Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

primary endpoint by demonstrating superior 24-hour bronchodilation to placeboat 12 weeks measured by trough FEV1 (i.e. forced expiratory volume in one second), a standard measure of lung function[1]. NVA237 was delivered using the Concept1® device, a single-dose dry-powder inhaler.

Key secondary endpoints were improvement in breathlessness assessed using the Transition Dyspnea Index (TDI) at 26 weeks, and improved quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) at 52 weeks. Important secondary endpoints were time to first COPD exacerbation and use of rescue medication during 52 weeks of treatment. The study met all of these endpoints.

The GLOW2 study also showed that NVA237 was well-tolerated with a similar incidence of adverse events for patients treated with NVA237, placebo and open-label tiotropium.

GLOW2 was a 52-week double-blind, placebo-controlled, parallel-group study involving 1,066 patients to assess the efficacy, safety and tolerability of NVA237 in patients with COPD. Patients were randomized into three treatment arms receiving either once-daily NVA237 50 mcg, placebo, or once-daily open-label tiotropium 18 mcg. They were also permitted to use COPD background therapy and rescue medication.

In April 2011 Novartis announced results from the first Phase III clinical trial with NVA237. The pivotal double-blind 26-week GLOW1 study met its primary endpoint by demonstrating superior bronchodilation to placebo at 12 weeks measured by trough FEV1 (p<0.001). The incidence of adverse events was similar in NVA237-treated patients and in those receiving placebo. Further data from GLOW1 will be presented at the European Respiratory Society congress in Amsterdam in September 2011.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura.  Novartis intends to launch NVA237 in 2012 as a once-daily monotherapy for COPD.  The first launch for Q
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Legal-Bay LLC, the Lawsuit Settlement Funding Company, ... multidistrict litigation (MDL) over the Zimmer NexGen Knee implant ... , 2015. There are currently more than a thousand ... a federal judge in Illinois . ... begin in October of this year. Zimmer Inc. previously ...
(Date:6/29/2015)... -- , Gerresheimer will sell its borosilicate glass ... into a 10-year-supply agreement for pharmaceutical glass tubing ... Corning and Gerresheimer will form a joint ... Gerresheimer,s outlook for the financial years 2016 to ... tubing business , In line with its strategy ...
(Date:6/29/2015)... 29, 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ... credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby ... of secured debt financing. CareView is an information technology ... monitoring. Under the credit agreement, PDL will ... financing in two tranches of $20 million, based upon ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 2Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
(Date:6/30/2015)... ... 30, 2015 , ... The board certified otolaryngologists at Clear ... to inform potential sinus surgery patients about ear, nose, and throat (ENT) ailments ... a wide variety of ENT issues including hearing loss, ear infections, dizziness, sleep ...
(Date:6/30/2015)... ... June 30, 2015 , ... Villa Health Care ... centers in the country. To spread the word, Villa Health Care Center created ... is, indeed, worthy of five stars. While Medicare centers its rating on health ...
(Date:6/30/2015)... ... 2015 , ... The LIV Fertility Center in Puerto Vallarta is ... age to pursue egg freezing. Statistics show that 20 percent of women are waiting ... percent increase since the 1970s. , Sadly, for women who have delayed parenthood for ...
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... Reasons You Have Acne ,” listed five triggers that most people would not ... cloths, hair care products, and toothpaste. The primary causes of acne are ...
Breaking Medicine News(10 mins):Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2
... A recently published study revealed that virological breakthrough (VBT) ... chronic hepatitis B. Nearly 40% of the VBTs found ... this retrospective study are published in the May issue ... on behalf of the American Association for the Study ...
... drug memantine submitted a supplementary analysis of study data, the ... sees proof of a benefit of the drug for cognitive ... of daily living, at least for a treatment period of ... benefit assessment of 2009. IQWiG had repeatedly called upon the ...
... Goodwin HealthDay Reporter , TUESDAY, April 26 (HealthDay ... attacks, such as clot-busting drugs and rapid angioplasty, has led ... Researchers used data from a Swedish coronary care registry ... type of deadly heart attack known as STEMI between 1996 ...
... for publication in The Endocrine Society,s Journal of Clinical ... white children with vitamin D deficiency both had higher fat ... of fat just under their skin and white children were ... internal organs. Studies in adults and children have shown ...
... , TUESDAY, April 26 (HealthDay News) -- Seniors who ... of developing Alzheimer,s disease, a new study suggests. ... house causes dementia, and other factors could explain the ... cost of isolation, said lead investigator Bryan D. James, ...
... University bioengineering students in collaboration with the Texas Heart ... to arrhythmia victims headed toward cardiac arrest. For ... created a unique pad system for automated external defibrillators ... back into a proper rhythm in an emergency. ...
Cached Medicine News:Health News:Hepatitis B virus reemerges with long-term nucleoside analog treatment 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 3Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 3Health News:Unique AED pads give hearts a second chance 2
For the quantitative determination of uric acid in serum....
For determination of uric acid in serum, plasma or urine. For Hitachi 704 / 911. Available with Calibrator: Trucal U and controls: Trulab N and Trulab P....
For the quantitative determination of uric acid in serum....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: